Brief: GenOway FY EBITDA Up At EUR 1.5 Million

genOway SA

28/03/2022 17:36

March 28 (Reuters) - Genoway SA  ALGEN.PA :
    * GROWTH IN 2022 IS EXPECTED TO BE SIMILAR TO 2021, DRIVEN
BY THE
EXPANSION OF THE CATALOG OFFER
    * FY EBITDA EUR 1.5 MILLION VERSUS EUR 1.0 MILLION YEAR AGO
    * FY NET LOSS EUR 0.3 MILLION VERSUS LOSS OF EUR 0.7 MILLION
YEAR
AGO
    * TO DATE, GENOWAY'S EXPOSURE TO THE RUSSIAN AND UKRAINIAN
MARKETS
IS VIRTUALLY NIL (LESS THAN 0.5% OF REVENUE) 
    * AVAILABLE CASH AMOUNTED TO €5.6 MILLION AT THE END OF 2021
COMPARED TO €2.7 MILLION ONE YEAR EARLIER
    * SHOULD ACHIEVE OBJECTIVES OF 2019-2024 STRATEGIC PLAN: TO
BECOME
WORLD LEADER IN PRECLINICAL IMMUNO-ONCOLOGY MODELS, TRIPLE SALES
TO EUR 30 MILLION AND ACHIEVE EBITDA MARGIN OF 25%

Source text for Eikon:  urn:newsml:reuters.com:*:nNDLbzbQZV
Further company coverage:  ALGEN.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))